Müllertz A - Search Results

1

In vivo in vitro correlations for a poorly soluble drug, danazol, using the flow-through dissolution method with biorelevant dissolution media.

Sunesen VH, Pedersen BL, Kristensen HG, Müllertz A. Sunesen VH, et al. Among authors: mullertz a. Eur J Pharm Sci. 2005 Mar;24(4):305-13. doi: 10.1016/j.ejps.2004.11.007. Epub 2005 Jan 6. Eur J Pharm Sci. 2005. PMID: 15734297

In vivo release profiles under fasted and fed conditions were obtained from a previous study by deconvolution [Sunesen, V.H., Vedelsdal, R., Kristensen, H.G., Christrup, L., Mullertz, A. 2005. Effect of liquid volume and food intake on the absolute bioavailab …

In vivo release profiles under fasted and fed conditions were obtained from a previous study by deconvolution [Sunesen, V.H., Vedelsd …

2

Dissolution of hydrocortisone in human and simulated intestinal fluids.

Pedersen BL, Brøndsted H, Lennernäs H, Christensen FN, Müllertz A, Kristensen HG. Pedersen BL, et al. Among authors: mullertz a. Pharm Res. 2000 Feb;17(2):183-9. doi: 10.1023/a:1007517414200. Pharm Res. 2000. PMID: 10751033

3

A comparison of the solubility of danazol in human and simulated gastrointestinal fluids.

Pedersen BL, Müllertz A, Brøndsted H, Kristensen HG. Pedersen BL, et al. Among authors: mullertz a. Pharm Res. 2000 Jul;17(7):891-4. doi: 10.1023/a:1007576713216. Pharm Res. 2000. PMID: 10990211 No abstract available.

4

The effect of alpha-tocopherol on the in vitro solubilisation of lipophilic drugs.

Nielsen PB, Müllertz A, Norling T, Kristensen HG. Nielsen PB, et al. Among authors: mullertz a. Int J Pharm. 2001 Jul 17;222(2):217-24. doi: 10.1016/s0378-5173(01)00701-3. Int J Pharm. 2001. PMID: 11427352

5

A dynamic in vitro lipolysis model. I. Controlling the rate of lipolysis by continuous addition of calcium.

Zangenberg NH, Müllertz A, Kristensen HG, Hovgaard L. Zangenberg NH, et al. Among authors: mullertz a. Eur J Pharm Sci. 2001 Sep;14(2):115-22. doi: 10.1016/s0928-0987(01)00169-5. Eur J Pharm Sci. 2001. PMID: 11500257

6

A dynamic in vitro lipolysis model. II: Evaluation of the model.

Zangenberg NH, Müllertz A, Kristensen HG, Hovgaard L. Zangenberg NH, et al. Among authors: mullertz a. Eur J Pharm Sci. 2001 Oct;14(3):237-44. doi: 10.1016/s0928-0987(01)00182-8. Eur J Pharm Sci. 2001. PMID: 11576829

7

Comparison of the lymphatic transport of halofantrine administered in disperse systems containing three different unsaturated fatty acids.

Holm R, Müllertz A, Pedersen GP, Kristensen HG. Holm R, et al. Among authors: mullertz a. Pharm Res. 2001 Sep;18(9):1299-304. doi: 10.1023/a:1013037927882. Pharm Res. 2001. PMID: 11683243

8

Comparison of total oral bioavailability and the lymphatic transport of halofantrine from three different unsaturated triglycerides in lymph-cannulated conscious rats.

Holm R, Müllertz A, Christensen E, Høy CE, Kristensen HG. Holm R, et al. Among authors: mullertz a. Eur J Pharm Sci. 2001 Dec;14(4):331-7. doi: 10.1016/s0928-0987(01)00186-5. Eur J Pharm Sci. 2001. PMID: 11684408

9

Comparison of the lymphatic transport of a lipophilic drug from vehicles containing alpha-tocopherol and/or triglycerides in rats.

Nielsen PB, Müllertz A, Norling T, Kristensen HG. Nielsen PB, et al. Among authors: mullertz a. J Pharm Pharmacol. 2001 Nov;53(11):1439-45. doi: 10.1211/0022357011777972. J Pharm Pharmacol. 2001. PMID: 11732746

10

Structured triglyceride vehicles for oral delivery of halofantrine: examination of intestinal lymphatic transport and bioavailability in conscious rats.

Holm R, Porter CJ, Müllertz A, Kristensen HG, Charman WN. Holm R, et al. Among authors: mullertz a. Pharm Res. 2002 Sep;19(9):1354-61. doi: 10.1023/a:1020311127328. Pharm Res. 2002. PMID: 12403073

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

243 results

Search Page